Prostate Cancer: Abiraterone
The question
To ask the Secretary of State for Health and Social Care, if he will make an estimate of the (a) cost per patient, (b) number of eligible patients, (c) net cost, (d) incremental quality-adjusted life years gained and (e) incremental cost-effectiveness ratio of extending abiraterone access to high-risk, non-metastatic prostate cancer patients in England.
Answered by Dr Zubir Ahmed
NHS England is unable to provide information related to the cost per patient as disclosure of this information could be used to identify the discounted price that we have agreed and would prejudice the commercial interests of both NHS England and the supplier.
The number of patients eligible for abiraterone for the treatment of high-risk, non-metastatic prostate cancer is between 7,500 and 9,500 per year.
The total net cost of the policy, including the drug cost, to NHS England is estimated to be approximately £49.36 million over five years.
NHS England has not calculated the incremental quality-adjusted life years gained or the incremental cost-effectiveness ratio because NHS England uses a relative prioritisation process for policy propositions that require funding in line with the published NHS England Specialised Commissioning Service Development Policy, which is available at the following link:
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →